{"disease":{"id":"clostridium-difficile-infection","name":"Clostridium difficile infection","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":3},"drugs":{"marketed":[{"drug_id":"fidaxomicin","indication_name":"Clostridium difficile infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dificid","generic_name":"FIDAXOMICIN","company_name":"Cubist Pharms Llc","drug_phase":"marketed","molecular_target":"","drug_class":"Macrolide Antibacterial [EPC]","quality_score":65,"revenue":"410.0","mechanism":"Dificid works by inhibiting protein synthesis in bacteria, preventing them from reproducing and causing infection."},{"drug_id":"bezlotoxumab","indication_name":"Clostridium difficile infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinplava","generic_name":"BEZLOTOXUMAB","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Zinplava works by binding to and neutralizing toxins produced by Clostridium difficile bacteria."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04014608","title":"Protocol for Admission Toxigenic C. Difficile Surveillance","phase":"","overall_status":"COMPLETED","enrollment_count":148549,"lead_sponsor_name":"Endeavor Health","has_results":false},{"nct_id":"NCT03349268","title":"Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection","phase":"NA","overall_status":"COMPLETED","enrollment_count":25732,"lead_sponsor_name":"University of Michigan","has_results":true},{"nct_id":"NCT03090191","title":"Clostridium Difficile Vaccine Efficacy Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":17535,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01887912","title":"Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":9302,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT03848689","title":"FQ Restriction for the Prevention of CDI","phase":"","overall_status":"COMPLETED","enrollment_count":5871,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false},{"nct_id":"NCT07261826","title":"Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Chen QiYi","has_results":false},{"nct_id":"NCT03503474","title":"COMBACTE-CDI Understanding the Burden of C. Difficile Infection","phase":"","overall_status":"COMPLETED","enrollment_count":3240,"lead_sponsor_name":"University of Leeds","has_results":true},{"nct_id":"NCT02968758","title":"Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains","phase":"NA","overall_status":"COMPLETED","enrollment_count":2461,"lead_sponsor_name":"Meridian Bioscience, Inc.","has_results":true},{"nct_id":"NCT01241552","title":"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1452,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02996487","title":"Screening to Prophylax Against Clostridium Difficile Infection -","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1294,"lead_sponsor_name":"Corewell Health East","has_results":true},{"nct_id":"NCT01513239","title":"A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1203,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04075422","title":"Bezlotoxumab - in \"Real Life\" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.","phase":"","overall_status":"COMPLETED","enrollment_count":869,"lead_sponsor_name":"Fundacion SEIMC-GESIDA","has_results":false},{"nct_id":"NCT05192148","title":"Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile","phase":"NA","overall_status":"UNKNOWN","enrollment_count":840,"lead_sponsor_name":"Fondation Hôpital Saint-Joseph","has_results":false},{"nct_id":"NCT03931941","title":"Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":793,"lead_sponsor_name":"Rebiotix Inc.","has_results":true},{"nct_id":"NCT04801862","title":"Natural History of Clostridioides Difficile Infection","phase":"","overall_status":"UNKNOWN","enrollment_count":750,"lead_sponsor_name":"Hospital Universitario de Valme","has_results":false},{"nct_id":"NCT01987895","title":"Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":632,"lead_sponsor_name":"Actelion","has_results":true},{"nct_id":"NCT01983683","title":"Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":631,"lead_sponsor_name":"Actelion","has_results":true},{"nct_id":"NCT01598311","title":"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":608,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT01597505","title":"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":606,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT04187430","title":"Validation of a Prediction Score for Recurrent C. Difficile Infection: Implementation for Treatment Algorithm Strategies","phase":"","overall_status":"UNKNOWN","enrollment_count":513,"lead_sponsor_name":"Emilio Bouza","has_results":false},{"nct_id":"NCT03562741","title":"Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile","phase":"NA","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Krunal Patel","has_results":false},{"nct_id":"NCT04567134","title":"Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Hanyang University Seoul Hospital","has_results":false},{"nct_id":"NCT04014413","title":"Safety and Efficacy of Fecal Microbiota Transplantation","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT03244644","title":"Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":320,"lead_sponsor_name":"Rebiotix Inc.","has_results":true},{"nct_id":"NCT06311006","title":"Safety Registry of a Fecal Microbiota Transplant Cohort","phase":"","overall_status":"RECRUITING","enrollment_count":305,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT02214771","title":"Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients","phase":"","overall_status":"COMPLETED","enrollment_count":296,"lead_sponsor_name":"Astellas Pharma S.A.S.","has_results":false},{"nct_id":"NCT04138706","title":"Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":263,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false},{"nct_id":"NCT04305769","title":"Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"University of Virginia","has_results":false},{"nct_id":"NCT03710694","title":"Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI)","phase":"NA","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Da Volterra","has_results":false},{"nct_id":"NCT04960306","title":"Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":238,"lead_sponsor_name":"University of Pecs","has_results":false},{"nct_id":"NCT03654872","title":"Clostridium Difficile Virulence Mechanism Study (CDVM Study)","phase":"","overall_status":"UNKNOWN","enrollment_count":227,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT04698148","title":"Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gastrointestinal Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":225,"lead_sponsor_name":"Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari","has_results":false},{"nct_id":"NCT01085591","title":"Study of CB-183,315 in Participants With Clostridium Difficile Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":210,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT03110133","title":"Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":206,"lead_sponsor_name":"Finch Research and Development LLC.","has_results":true},{"nct_id":"NCT03183128","title":"ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"Seres Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04317963","title":"Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection","phase":"","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"University of Illinois at Chicago","has_results":false},{"nct_id":"NCT07221370","title":"Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":176,"lead_sponsor_name":"Riverside University Health System Medical Center","has_results":false},{"nct_id":"NCT01259726","title":"Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT03834038","title":"Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridioides Difficile Infection","phase":"NA","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"Vancouver Island Health Authority","has_results":true},{"nct_id":"NCT03005379","title":"Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":153,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT06703918","title":"Study on Clostridium Difficile Infection in Infants","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"First People's Hospital of Hangzhou","has_results":false},{"nct_id":"NCT03182907","title":"Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05835219","title":"REBYOTA™ Prospective Registry","phase":"","overall_status":"COMPLETED","enrollment_count":145,"lead_sponsor_name":"Ferring Pharmaceuticals","has_results":false},{"nct_id":"NCT02692651","title":"A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"University of Michigan","has_results":true},{"nct_id":"NCT05008640","title":"Creation of an E-toileting Log Through Classification of the Physical Properties of Stool and Urine Using TrueLoo™","phase":"","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"Toi Labs, Inc.","has_results":false},{"nct_id":"NCT03497806","title":"Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":132,"lead_sponsor_name":"Finch Research and Development LLC.","has_results":true},{"nct_id":"NCT04415918","title":"Bezlotoxumab Efficacy and Tolerability in Cancer Patient","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":132,"lead_sponsor_name":"The Cooper Health System","has_results":false},{"nct_id":"NCT03796650","title":"Fecal Transplantation for Primary Clostridium Difficile Infection","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":104,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT03466502","title":"Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"University of Nevada, Reno","has_results":false},{"nct_id":"NCT03712722","title":"Fecal Microbiota Transplantation (FMT) for Clostridium Difficile","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"University of Aarhus","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}